RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma
Open Access
- 18 December 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (4) , 4279-4297
Abstract
Methylation of the Ras-association domain family 10 (RASSF10) promoter region correlates with clinicopathological characteristics and poor prognosis in several human cancers. Here, we examined RASSF10 expression in hepatocellular carcinoma (HCC) and its role in hepatocarcinogenesis. RASSF10 mRNA and protein levels were downregulated in both HCC cell lines and patient tissue samples. In patient tissues, low RASSF10 levels correlated with hepatocirrhosis, poor tumor differentiation, tumor thrombus and Barcelona Clinic Liver Cancer stage, and were indicative of increased tumor recurrence and reduced patient survival. Low RASSF10 expression was associated with promoter hypermethylation, which was in turn associated with polycyclic aromatic hydrocarbon and aflatoxin B1 exposure, but not DNA methyltransferase expression. Overexpression of RASSF10 in HCC cell lines suppressed cell growth and colony formation, and induced apoptosis by up- or down-regulating specific Bcl-2 family proteins. RASSF10 overexpression increased pro-apoptotic Bax and Bad levels, but decreased anti-apoptotic Bcl-2 and Bcl-xl expression. Overexpression also inhibited tumor formation in nude mice and reduced cell migration and invasion by inhibiting the epithelial-mesenchymal transition. RASSF10 knockdown promoted cell growth. Our results show that RASSF10 is frequently hypermethylated and down-regulated in HCC and can potentially serve as a useful biomarker predictive of HCC patient prognosis.Keywords
This publication has 49 references indexed in Scilit:
- Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell CarcinomaCancers, 2013
- Human hepatocyte carcinogenesisInternational Journal of Oncology, 2013
- The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancerOncogenesis, 2012
- CpG Site–Specific Hypermethylation of p16INK4α in Peripheral Blood Lymphocytes of PAH-Exposed WorkersCancer Epidemiology, Biomarkers & Prevention, 2012
- N-terminal RASSF familyEpigenetics, 2011
- The RASSF proteins in cancer; from epigenetic silencing to functional characterizationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Identification of Cell-Active Lysine Specific Demethylase 1-Selective InhibitorsJournal of the American Chemical Society, 2009
- The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemiasMolecular Cancer, 2009
- RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong CountyJournal of Gastroenterology and Hepatology, 2008
- DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinomaCancer Letters, 2006